Nodality makes Laura Brege CEO
This article was originally published in Scrip
Executive Summary
Privately-held biotechnology company Nodality, which is focused on improving the development and clinical use of therapeutics in cancer and autoimmune disease through the application of its Single Cell Network Profiling technology, has made Laura Brege president and chief executive officer. Prior to joining Nodality, Ms Brege held several senior-level positions at Onyx Pharmaceuticals.